Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Royal Philips (Koninklijke Philips N.V., NYSE: PHG) is a health technology company whose news flow centers on diagnostic imaging, ultrasound, image-guided therapy, monitoring, enterprise informatics and personal health. Company announcements frequently highlight AI-enabled systems, new product launches and strategic portfolio moves, giving investors and observers insight into how Philips develops and positions its health technology offerings.
Recent Philips news has featured AI-powered innovations in image-guided therapy and diagnostic imaging, such as LumiGuide 3D Device Guidance for light-based navigation during minimally invasive procedures, DeviceGuide for AI-assisted tracking of heart valve repair devices, and Verida, a detector-based spectral CT system with AI integrated across the imaging chain. The company also reports advances in MRI through its BlueSeal Horizon 3.0T platform and extended partnerships in neuroimaging, such as the integration of Cortechs.ai quantitative analytics into Philips MR workflows.
News items also cover enterprise informatics and cloud-based solutions, including the launch of Philips Management 15, a web-based diagnostic viewer that delivers full radiology capabilities through a browser and interfaces with AI tools and interactive reporting. In addition, Philips communicates on long-term partnerships with health systems, monitoring agreements and large-scale deployments of its Azurion image-guided therapy systems.
Corporate and portfolio developments appear regularly in the news stream. Examples include the agreement to acquire SpectraWAVE Inc. to expand intravascular imaging and physiology solutions, and the completed carve-out of the Philips Emergency Care business, which now operates as Heartstream under a Philips brand license. Earnings-related releases and Form 6-K summaries provide context on comparable order intake, sales trends, margins, productivity programs and outlook.
Investors and healthcare professionals following PHG news can use this page to track product introductions, AI and imaging milestones, strategic transactions and quarterly performance updates that shape Philips’ role in global health technology.
Royal Philips (NYSE: PHG) received FDA 510(k) clearance on April 16, 2026 for the Philips Spectral CT Verida, the company’s AI-powered, detector-based spectral CT system. Verida combines always-on dual-layer detection with an AI deep-learning reconstruction (Spectral Precise Image), reconstructing 145 images/sec and producing full exams in under 30 seconds, enabling up to 270 exams per day. Indications include radiology, interventional radiology, cardiology, oncology, and low-dose lung cancer screening within established protocols. Certain features have use limitations (pediatric validation and treatment-planning-specific modes); Spectral Precise Image is supplemental to clinical judgment.
Philips (NYSE: PHG) announced that Carla Goulart Peron, MD, Chief Medical Officer at Philips, was appointed to the Board of Directors of the Medical Device Innovation Consortium (MDIC) on April 2, 2026.
The appointment links Philips’ medical leadership with MDIC’s regulatory science and device-evidence initiatives to support patient access to safe medical technologies.
Royal Philips (NYSE: PHG) received FDA 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, an AI-powered solution that provides real-time visualization and navigation during minimally invasive mitral transcatheter edge-to-edge repair (M-TEER).
DeviceGuide auto-tracks the Edwards PASCAL Ace device, integrates live 3D echo and X-ray via Azurion and EPIQ platforms, was developed with Edwards Lifesciences, and will be showcased at ACC 2026. Commercial availability is subject to market release and regional regulatory clearance.
Philips (NYSE:PHG) launched IntraSight Plus, an interventional cardiology platform cleared by the FDA 510(k) and CE marked for the USA and Europe. The system combines Class IA IVUS, iFR/FFR physiology, co-/tri-registration and real-time device visualization, and claims up to 47% system operation time savings. A first patient case occurred on March 19, 2026, enabling complete revascularization using integrated tri-registered imaging and physiology at the bedside. Commercial availability depends on market release and local regulatory requirements.
Royal Philips (NYSE: PHG) ranked No. 1 among medtech companies in the European Patent Office Technology Dashboard 2025 and remained the largest Dutch patent applicant with 1,289 European patent applications across domains and 676 Medtech filings in 2025. Philips invested > 9% of sales in R&D in 2025 and reported ~53,000 patent rights.
The company highlighted platform-based hardware, software, data and AI solutions and said its innovation improved the lives of 2 billion people in 2025, targeting 2.5 billion lives per year by 2030.
Royal Philips (NYSE: PHG) has convened its Annual General Meeting of Shareholders (AGM) 2026 and published the agenda with explanatory notes. The AGM is scheduled for Friday, May 8, 2026 at 10:00 CET at Hotel Okura Amsterdam.
Key items include the proposed appointment of John DeFord to the Supervisory Board; re-appointments of Paul Stoffels, Herna Verhagen, and Sanjay Poonen; and re-appointment of Roy Jakobs as President/CEO and Board of Management member, all effective May 8, 2026. The agenda also covers the 2025 Remuneration Report (advisory), a proposed Supervisory Board Remuneration Policy, adoption of financial statements, and dividend options.
Royal Philips (NYSE: PHG) proposed the appointment of John DeFord to its Supervisory Board and re-appointments of Paul Stoffels, Herna Verhagen and Sanjay Poonen.
Marc Harrison will step down after two terms. The Supervisory Board also reconfirmed the previously announced re-appointment proposal for Roy Jakobs as President/CEO. AGM set for 8 May 2026.
Philips Sonicare (NYSE: PHG) declared World Oral Health Night for March 20, 2026, showcasing what manual brushing can leave behind and promoting power brushing benefits.
Highlights: a public installation in New York City (Lavan Midtown, 2–8 p.m. ET), research cited that manual brushing can leave up to 50% plaque, and product claims that Sonicare removes up to 2000% more plaque with up to 62,000 bristle movements/min. The new Sonicare 6500 is said to remove 1000% more plaque versus a manual brush.
Philips (NYSE: PHG) expanded its digital pathology portfolio on March 11, 2026 with Philips IntelliSite Pathology Solution on HealthSuite, a fully cloud-enabled offering powered by Amazon Web Services to help labs scale digital workflows, store and review high-resolution pathology images, and enable remote collaboration and AI integration.
The solution builds on Philips’ FDA-cleared scanners, existing installed base and HealthSuite Integrated Diagnostics portfolio; availability and AI features are limited in certain jurisdictions, including the USA.
Philips (NYSE: PHG) showcased platform-based connected care intelligence at HIMSS26 on March 10, 2026, focusing on enterprise patient monitoring and Integrated Diagnostics.
Philips emphasized interoperable, AI-enabled platforms that link monitoring, imaging, EMR and third-party systems to create longitudinal patient visibility, reduce fragmentation, and accelerate diagnostic insight; the Future Health Index 2025 found 77% of clinicians lost time due to inaccessible patient data.